Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the Company’s anti-CD19 monoclonal antibody inebilizumab, an investigational monotherapy for neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, life-threatening autoimmune disease affecting the central nervous system.
{iframe}https://www.businesswire.com/news/home/20190418005188/en/Viela-Bio-Receives-U.S.-FDA-Breakthrough-Therapy#.XLhql4RSvEU.linkedin{/iframe}